Inhibitex announces license and commercialization agreement with 3M (INHX) 1.72 : Co announces that it has entered into a license and commercialization agreement with 3M (MMM) for the development of various diagnostic products using INHX's MSCRAMM protein platform. Under the terms of the agreement, INHX granted 3M an exclusive global license to use Clumping Factor A, an MSCRAMM protein, in the development of diagnostic products in exchange for license fees, future milestone payments, financial support of further research and development activities and royalty payments on product sales that will exceed $4.0 mln in cash considerations over the next five years. Co says 3M also received a license to use additional MSCRAMM protein targets for the development of other diagnostic products.